1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-17 am EDT
560.60 CHF   +0.39%
08/04Merck KGaA profit gets boost from dollar, outweighing higher costs
RE
07/28LONZA : Half-Year Alternative Performance Measures Report
PU
07/25AlphaValue/Baader Europe Lifts Price Target on Lonza, Maintains Add Recommendation
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/11/2022 08/12/2022 08/15/2022 08/16/2022 08/17/2022 Date
584(c) 570.2(c) 569.6(c) 558.4(c) 560.6 Last
153 529 143 965 85 246 98 514 89 916 Volume
+2.49% -2.36% -0.11% -1.97% +0.39% Change
More quotes
Estimated financial data (e)
Sales 2022 6 208 M 6 532 M 6 532 M
Net income 2022 1 037 M 1 091 M 1 091 M
Net cash position 2022 347 M 365 M 365 M
P/E ratio 2022 40,8x
Yield 2022 0,58%
Sales 2023 6 946 M 7 308 M 7 308 M
Net income 2023 1 263 M 1 329 M 1 329 M
Net cash position 2023 90,7 M 95,4 M 95,4 M
P/E ratio 2023 33,8x
Yield 2023 0,64%
Capitalization 41 427 M 43 587 M 43 587 M
EV / Sales 2022 6,62x
EV / Sales 2023 5,95x
Nbr of Employees 17 154
Free-Float 99,6%
More Financials
Company
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (49.9%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (22.3%). In addition, the group... 
More about the company
Ratings of Lonza Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about LONZA GROUP AG
08/04Merck KGaA profit gets boost from dollar, outweighing higher costs
RE
07/28LONZA : Half-Year Alternative Performance Measures Report
PU
07/25AlphaValue/Baader Europe Lifts Price Target on Lonza, Maintains Add Recommendation
MT
07/22TRANSCRIPT : Lonza Group AG, H1 2022 Earnings Call, Jul 22, 2022
CI
07/22Lonza Group Profit Balloons 89% in H1 as Sales Rises 17%
MT
07/22Lonza Confident on 2022 Goals as 1st Half Sales Book Healthy Rise
DJ
07/22Lonza's H1 Attributable Profit Jumps With 17% Sales Growth, Confirms FY22 Outlook
MT
07/22Lonza's first-half core EBITDA gains 16.5%
RE
07/22LONZA : Half-Year Results Report
PU
07/22LONZA : Half-Year Results Presentation
PU
07/22Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE ..
EQ
07/22Lonza Group AG Reports Earnings Results for the Half Year Ended June 30, 2022
CI
07/22Lonza Group AG Reconfirms Sales Guidance for the Years 2022 and 2024
CI
07/22LONZA GROUP AG : Press Release
CO
07/22LONZA GROUP AG : Half-year results
CO
More news
News in other languages on LONZA GROUP AG
08/16Aktien Schweiz schließen etwas leichter - Straumann unter Druck
08/10L'inflation à quitte ou double
08/10AVIS D'ANALYSTES DU JOUR : Aperam, Evotec, Hugo Boss, Lonza, Prysmian, Genmab, Pets at Hom..
08/03BOLSA DE MADRID : Para relajarse, tendrá que volver más tarde
08/03Pour la détente, il faudra repasser
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 558,40 CHF
Average target price 756,58 CHF
Spread / Average Target 35,5%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Maria Soler Nunez Head-Group Operations
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-26.68%43 587
MODERNA, INC.-33.87%65 706
IQVIA HOLDINGS INC.-13.27%45 640
SEAGEN INC.10.30%31 450
ALNYLAM PHARMACEUTICALS, INC.34.54%27 384
CELLTRION, INC.6.57%22 159